Qualigen Therapeutics, Inc. — Director's Dealing 2020

May 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Qualigen Therapeutics, Inc. (QLGN)
CIK: 0001460702
Period of Report: 2020-05-22

Reporting Person: Lotz Christopher L. (VP of Finance, CFO.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-22	Common Stock	J	9841	—	Acquired	9841	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-22	Warrant (Right to Buy)	$2.0663	J	22142	Acquired	2024-01-31	Common Stock (22142)	Direct
2020-05-22	Warrant (Right to Buy)	$2.0663	J	29847	Acquired	2024-08-02	Common Stock (29847)	Direct
2020-05-22	Warrant (Right to Buy)	$2.5405	J	22142	Acquired	2025-03-02	Common Stock (22142)	Direct
2020-05-22	Warrant (Right to Buy)	$2.5405	J	3543	Acquired	2026-09-22	Common Stock (3543)	Direct

Footnotes

F1: On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer of the Issuer.

F2: Immediately prior to the Closing, the Reporting Person was a stockholder of Qualigen. Pursuant to the Merger, the shares of Qualigen common stock previously held by the Reporting Person were converted into 9,841 shares of common stock of the Issuer.

F3: Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.